Dataset Information

Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence.

ABSTRACT: To assess the capability of perfusion MRI to differentiate between necrosis and tumor recurrence in patients showing radiological progression of cerebral metastases treated with stereotactic radiosurgery (SRS). From 2004 to 2006 dynamic susceptibility-weighted contrast-enhanced perfusion MRI scans were performed on patients with cerebral metastasis showing radiological progression after SRS during follow-up. Several perfusion MRI characteristics were examined: a subjective visual score of the relative cerebral blood volume (rCBV) map and quantitative rCBV measurements of the contrast-enhanced areas of maximal perfusion. For a total of 34 lesions in 31 patients a perfusion MRI was performed. Diagnoses were based on histology, definite radiological decrease or a combination of radiological and clinical follow-up. The diagnosis of tumor recurrence was obtained in 20 of 34 lesions, and tumor necrosis in 14 of 34. Regression analyses for all measures proved statistically significant (chi(2) = 11.6-21.6, P < 0.001-0.0001). Visual inspection of the rCBV map yielded a sensitivity and specificity of 70.0 respectively 92.9%. The optimal cutoff point for maximal tumor rCBV relative to white matter was 2.00 (improving the sensibility to 85.0%) and 1.85 relative to grey matter (GM), improving the specificity to 100%, with a corresponding sensitivity of 70.0%. Perfusion MRI seems to be a useful tool in the differentiation of necrosis and tumor recurrence after SRS. For the patients displaying a rCBV-GM greater than 1.85, the diagnosis of necrosis was excluded. Salvage treatment can be initiated for these patients in an attempt to prolong survival.

SUBMITTER: Hoefnagels FW

PROVIDER: S-EPMC2698975 | biostudies-other | 2009 Jun

REPOSITORIES: biostudies-other

ACCESS DATA

Similar Datasets

Project description:BackgroundSpinal metastasis and multiple myeloma share many overlapping conventional radiographic imaging characteristics, thus, their differentiation may be challenging. The purpose of this study was to develop and validate an MRI-based radiomics nomogram for the differentiation of spinal metastasis and multiple myeloma.Materials and methodsA total of 312 patients (training set: n = 146, validation set: n = 65, our center; external test set: n = 101, two other centers) with spinal metastasis (n = 196) and multiple myeloma (n = 116) were retrospectively enrolled. Demographics and MRI findings were assessed to build a clinical factor model. Radiomics features were extracted from MRI images. A radiomics model was constructed by the least absolute shrinkage and selection operator method. A radiomics nomogram combining the radiomics signature and independent clinical factors was constructed. And, one experienced radiologist reviewed the MRI images for all case. The diagnostic performance of the different models was evaluated by receiver operating characteristic curves.ResultsA clinical factors model was built based on heterogeneous appearance and shape. Twenty-one features were used to build the radiomics signature. The area under the curve (AUC) values of the radiomics nomogram (0.853 and 0.762, respectively) were significantly higher than that of the clinical factor model (0.692 and 0.540, respectively) in both validation (p = 0.048) and external test (p < 0.001) sets. The AUC values of the radiomics nomogram model were higher than that of radiologist in training, validation and external test sets (all p < 0.05). Moreover, no significant difference in AUC values of radiomics nomogram model was found between the validation set and external test set (p = 0.212).ConclusionThe radiomics nomogram can differentiate spinal metastasis and multiple myeloma with a moderate to good performance, and may be as a valuable method to assist in the clinical diagnosis and preoperative decision-making.

Project description:PurposeThis retrospective study aimed to determine the prognostic factors associated with overall survival after intracranial local and distant recurrence in patients undergoing stereotactic radiosurgery (SRS) for brain metastases.Patients and methodsClinical characteristics and therapeutic parameters of 251 patients, who were treated with initial stereotactic radiosurgery for brain metastases and later experienced intracranial recurrence, were analyzed to identify prognostic factors of post-recurrence overall survival (PROS). A Cox proportional hazard model was applied for univariate and multivariate analyses.ResultsAmong the 251 patients, the median post-recurrence overall survival was 8 months, and the six-month PROS rate was 60.2%. The interval from initial radiosurgery treatment to intracranial recurrence (hazard ratio [HR]:0.970), the number of brain recurrent tumors (HR:1.245), the number of extracranial metastatic organs (HR:1.183), recursive partition analysis (RPA) (HR:1.778), and Eastern Cooperative Oncology Group Performance Status (ECOG PS) (HR:2.442) were identified as independent prognostic factors. The patients who received local treatment for solitary brain recurrence achieved better survival (the median survival time after recurrence was 22 months). In patients without extracranial metastasis, the median post-recurrence overall survival of the local treatment group was longer than that in the whole brain radiation therapy (WBRT) group (P<0.001) and the systemic therapy group (P<0.001).ConclusionA shorter interval from initial stereotactic radiosurgery to recurrence, an increasing number of brain recurrences and extracranial metastatic organs, and poor RPA and ECOG PS values are associated with poor post-recurrence prognosis. When the number of brain recurrent tumors and extracranial metastatic organs was limited, local treatment including stereotactic radiosurgery, surgery or intensity-modulated radiation therapy (IMRT) improved the post-recurrence overall survival.

Dataset Information

Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets